The antiretroviral agents currently recommended for the treatment of HIV are all characterized by high efficacy and safety \[[@CIT0001]\]. In particular, integrase inhibitors (INSTIs) constitute the preferred anchor drugs in modern first-line antiretroviral therapy (ART), thanks to their demonstrated durable virologic efficacy \[[@CIT0004]\], and are characterized by a low rate of adverse events \[[@CIT0005]\] and a favorable metabolic profile in lipids compared with protease inhibitors (PIs) and efavirenz \[[@CIT0006]\]. INSTI, together with rilpivirine and doravirine, is the drug recommended for treating people with HIV (PWH) with high cardiovascular risk \[[@CIT0004]\]. However, a new side effect has emerged in recent years, affecting the class of INSTIs in general and dolutegrvir (DTG) in particular, namely an unexpected excess in weight gain during the course of treatment \[[@CIT0009]\]. The impact of this effect on metabolic and cardiovascular outcomes is still unclear at this time \[[@CIT0011]\], sparking a heated debate between those who attribute weight gain to a return-to-health phenomenon and those who interpret it as an undesired side effect that could influence cardiovascular risk. Although the mechanisms underlying weight gain still remain unclear, the main characteristics of PWH gaining weight have been previously reported to be lower CD4 T-cell count \[[@CIT0013]\], higher HIV-RNA \[[@CIT0013], [@CIT0015]\], low baseline body mass index (BMI) \[[@CIT0014]\], female sex \[[@CIT0013], [@CIT0015], [@CIT0016]\] and older age \[[@CIT0013], [@CIT0014]\]. Regarding the association between weight gain and specific drugs, many studies have highlighted a role of DTG that is more evident in ART-naïve PWH \[[@CIT0011], [@CIT0013], [@CIT0015]\] and less consistent in ART-experienced PWH \[[@CIT0014], [@CIT0017], [@CIT0018]\]. However, DTG is usually administered in combination regimens that include other antiretrovirals, whose role in weight gain has been poorly studied and is not well understood. Backbones such as abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/FTC) seem to have a neutral effect on weight, BMI, and lean body mass changes according to 1 previous study \[[@CIT0019]\], but, on the other hand, a significant role of tenofovir alafenamide (TAF) over TDF has been reported for weight increase \[[@CIT0013], [@CIT0015], [@CIT0020]\]. The aim of the present study was to describe the weight changes in both naïve and experienced PWH, all treated with DTG, in a large prospective cohort and explore the role of the different antiretrovirals used in combination with DTG in weight gain. Secondary aims were clarifying if weight gain is associated with changes in lipids and fasting glucose and describing incident obesity and metabolic syndrome among PWH receiving DTG-based therapies.

METHODS {#s1}
=======

We analyzed data from the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective database. The SCOLTA project is a multicenter observational study that started in 2002 and that prospectively follows PWH who start to take new antiretroviral drugs, with the aim of identifying toxicities and adverse events in a real-life setting \[[@CIT0021]\]. Both ART-naïve and -experienced PWH can be included in SCOLTA if they are aged \>18 years and agree to enter the study. Clinical data collected include sex, age, ethnicity, weight, height, and history of previous ART. Laboratory data include HIV-RNA, CD4 T-cell count, CD4/CD8 ratio, total cholesterol (TC), high-density lipoprotein cholesterol (HDL), triglycerides (TGs), and fasting glucose and are prospectively collected in anonymous form in a central database every 6 months.

We performed a query to this prospectively collected database including participants on DTG enrolled from July 2014 until December 2019 (date of last extraction) for whom weight was registered at baseline (time of initiating DTG) and who had at least 1 follow-up. Female PWH who became pregnant during the study period were excluded. Moreover, we did not consider ART combinations that were used in ≤10 cases. Comparisons of patient demographics and baseline characteristics among different groups of backbones associated with DTG were performed using the chi-square test, analysis of variance, and the Mann-Whitney *U* test. Weight change from baseline was assessed using a paired *t* test in the univariate analysis at 6, 12, 18, and 24 months of follow-up. Overall weight change across follow-up visits (from baseline to month 24) was analyzed using a mixed model for repeated measures. We compared weight change among backbone groups, including potential confounders (differences between treatment groups or associated with baseline weight). Active hepatitis C virus (HCV) infection and statin use were updated over time. If weight was not measured at a follow-up visit, we imputed the missing value as the mean of the previous and the following visits.

Moreover, with the aim of identifying the factors associated with clinically significant weight gain, we defined as weight gainers (WGs) as those participants whose weight increased by at least 10% from baseline \[[@CIT0015]\]. The associations among ART regimens, participant characteristics, and being WGs were evaluated with hazard ratios (HRs) and 95% confidence intervals (CIs) using a Cox proportional hazard regression model; time was calculated as days between starting a DTG-including regimen and the visit where the ≥10% increase was measured. Variables included in the model were age, sex, baseline weight, risk factor for HIV acquisition, baseline CD4 and Centers for Disease Control and Prevention (CDC) stage, naïve status, ART duration (set at 0 for naïve participants), statin use, HCV eradication during the first year of study, and type of DTG-including regimen.

The impact of weight gain on lipids and glucose metabolism was explored by comparing TC, HDL, TC/HDL ratio, TG, and fasting glucose changes at 6 and 12 months between participants whose weight increased by at least 10% in the first year and those whose weight did not, using a general linear model including potential confounders. For this analysis, participants with weight gain ranging from \>1% to \<10% in the first year of observation were excluded. Participants whose weight increased ≤1% or decreased were defined as nongainers (NGs). We also evaluated the frequency of incident obesity and metabolic syndrome. Obesity was defined by a body mass index (BMI) \>30 kg/m^2^, while metabolic syndrome was defined by the presence of central obesity (assumed in PWH with BMI \>30 kg/m^2^) and any 2 of the following factors: (1) TG ≥150 mg/dL or treatment for hypertriglyceridemia; (2) HDL \<40 mg/dL for males or \<50 mg/dL for females or specific treatment for this lipid abnormality; (3) raised blood pressure, with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; (4) fasting glucose ≥100 mg/dL or diagnosis of type 2 diabetes \[[@CIT0022], [@CIT0023]\]. The study protocol of the SCOLTA group was approved by local ethical committees and conducted in accordance with the ethical principles stated in the Declaration of Helsinki. Written consent was obtained from all participants.

RESULTS {#s2}
=======

At the time of this analysis (December 2019), 987 PWH were enrolled in the SCOLTA cohort and on treatment with a DTG-containing regimen. Seven hundred sixty-six met the selection criteria for this analysis: weight available at baseline and at 6-month follow-up. Among these, 53 received a regimen used in \<10 cases and were excluded.

Characteristics of the Study Population {#s3}
---------------------------------------

A total of 713 participants (mean age \[SD, range\], 47.2 \[11.6, 19--81\] years) were included in the present analysis. Women represented 25.3% of the sample (n = 180, of whom 2 were transgender women), and 648 participants were Caucasian (90.9%); 22.3% were in CDC stage C (n = 159). One hundred ninety-five (27.4%) started DTG as their first ART regimen, whereas the remaining 518 (72.6%) were ART-experienced PWH who switched to DTG after a median (interquartile range \[IQR\]) of 9.8 (4.3--17.4) years of previous ART. DTG was associated with ABC/3TC in 326 participants (45.7%), TDF/FTC in 148 (20.8%), atazanavir or darunavir (boosted with ritonavir or cobicistat) in 60 (8.4%), rilpivirine in 45 (6.3%), 3TC in 75 (10.5%), and TAF/FTC in 59 (8.3%). Mean baseline weight (SD) was 69.2 (12.8) kg in naïve and 71.0 (13.6) kg in experienced participants. Further characterization of the study population is given in [Table 1](#T1){ref-type="table"}. Participants in different groups of treatment were different in terms of age, risk factor for HIV acquisition, naïve status, initial CD4 T-cell count and CD4/CD8 ratio, and active HCV infection. Among ART-experienced participants, a difference also existed in terms of detectable HIV-RNA at baseline and years of ART before DTG treatment. Among the participants, 535, 407, and 332 reached 12-, 18-, and 24-month follow-up. The median observation time (IQR) was 28 (11--39) months.

###### 

Characteristics of 713 Participants in the SCOLTA Dolutegravir Cohort, According to Antiretroviral Regimen

                                                                           Total               3TC+DTG             RPV+DTG             PI+DTG              3TC/ABC/DTG         TDF/FTC+DTG         TAF/FTC+DTG         
  ------------------------------------------------------------------------ ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ---------
  Sex M, No. (%)                                                           533 (74.7)          59 (78.7)           26 (57.8)           45 (75.0)           244 (74.8)          111 (75.0)          48 (81.4)           .12
  Age, mean ± SD, y                                                        47.2 ± 11.6         50.6 ± 11.1         51.8 ± 10.8         50.4 ± 11.3         46.9 ± 11.5         45.0 ± 11.2         43.8 ± 12.4         \<.0001
  Caucasian, No. (%)                                                       648 (90.9)          69 (92.0)           43 (95.6)           55 (91.7)           294 (90.2)          139 (93.9)          48 (81.4)           .09
  Weight, mean ± SD, kg                                                    70.5 ± 13.4         73.3 ± 13.9         70.2 ± 13.3         70.4 ± 11.5         69.8 ± 13.1         70.6 ± 14.6         71.4 ± 13.0         .46
  BMI (n = 608), mean ± SD, kg/m^2^                                        24.2 ± 4.0          24.5 ± 3.5          25.0 ± 3.8          24.2 ± 3.5          24.0 ± 4.0          24.0 ± 4.2          24.7 ± 4.3          .61
  Risk factor for HIV acquisition, No. (%)                                                                                                                                                                             
  Sexual                                                                   513 (72.0)          59 (78.7)           33 (73.3)           39 (65.0)           245 (75.2)          85 (57.4)           52 (88.1)           
  IVDU                                                                     112 (15.7)          8 (10.7)            11 (24.2)           14 (23.3)           42 (12.8)           32 (21.6)           5 (8.5)             \<.0001
  Other                                                                    88 (12.3)           8 (10.7)            1 (2.2)             7 (11.7)            39 (12.0)           31 (21.0)           2 (3.4)             
  CD4, mean ± SD, cells/mL                                                 570 ± 367           725 ± 422           699 ± 318           614 ± 317           617 ± 359           419 ± 330           364 ± 312           \<.0001
  CD4/CD8 (n = 616), median (IQR)                                          0.64 (0.34--0.99)   0.90 (0.57--1.23)   0.92 (0.62--1.14)   0.67 (0.50--0.97)   0.68 (0.41--1.03)   0.44 (0.17--0.74)   0.38 (0.11--0.67)   \<.0001
  Naïve, No. (%)                                                           195 (27.4)          5 (6.7)             1 (2.2)             1 (1.7)             75 (23.0)           68 (45.9)           45 (76.3)           \<.0001
  CDC stage C, No. (%)                                                     159 (22.3)          10 (13.3)           9 (20.0)            20 (33.3)           69 (21.2)           38 (25.7)           13 (22.0)           .07
  HIV-RNA \>50 copies/mL (experienced participants), No. (%)               95 (18.3)           6 (8.6)             1 (2.3)             22 (37.3)           39 (15.5)           24 (30.0)           3 (21.4)            \<.0001
  Years of ART (experienced participants), median (IQR)                    9.8 (4.3--17.4)     10.8 (7.5--17.6)    12.1 (6.7--18.3)    13.5 (6.8--19.2)    7.9 (4.0--15.5)     9.2 (3.2--17.3)     9.1 (4.5--19.0)     .004
  HCV active infection (baseline), No. (%)                                 66 (9.3)            2 (2.7)             2 (4.4)             7 (11.7)            27 (8.3)            25 (16.9)           3 (5.1)             .004
  HCV eradication during follow-up (n = 66), No. (%)                       30 (45.4)           0 (0)               1 (50.0)            3 (42.9)            15 (55.6)           10 (40.0)           1 (33.3)            .66
  Statin use at baseline, No. (%)                                          65 (9.1)            11 (14.7)           7 (15.6)            9 (15.0)            26 (8.0)            9 (6.1)             3 (5.1)             .05
  Statin started during the first year of observation (n = 648), No. (%)   17 (2.6)            2 (3.1)             3 (7.9)             2 (3.9)             6 (2.0)             3 (2.2)             1 (1.8)             .38

Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BMI, body mass index; CDC, Centers for Disease Control and Prevention; DTG, dolutegravir; FTC, emtricitabine; HCV, hepatitis C virus; IQR, interquartile range; IVDU, intravenous drug use; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); SCOLTA, Surveillance Cohort Long-Term Toxicity Antiretrovirals; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

Weight Gain in Different ART Regimens {#s4}
-------------------------------------

At baseline, women, participants in CDC stage C, and those with active HCV infection had significantly lower weight, whereas participants on statins were heavier than those not on statins. These findings were consistent in naïve and experienced participants, even if in some cases the probability for these comparisons was higher than the value set for significance (\<.05) because of the loss of power due to subgroup analysis. The mean weights of the participants in different DTG-based regimens at baseline and during follow-up are shown in [Figure 1](#F1){ref-type="fig"}. At 6 and 12 months, the mean weight change from baseline (± SE) was +0.6 ± 0.1 kg (*P* = .0005) and +1.2 ± 0.2 kg (*P* \< .0001), respectively, in the whole study population; the same figures were +1.2 ± 0.3 kg (*P* \< .0001) and +2.4 ± 0.4 kg (*P* \< .0001) in naïve and +0.4 ± 0.2 kg (*P* = .02) and +0.9 ± 0.2 kg (*P* \< .0001) in experienced participants. Weight over time was analyzed including age, sex, risk factor for HIV acquisition, CD4 at baseline, naïve status, CDC stage C, updated statin use, and DTG-including ART. We found that weight significantly increased and that naïve status (*P* = .002) and type of ART regimen (*P* = .033) affected weight gain over time. [Table 2](#T2){ref-type="table"} shows the mean change from baseline by ART regimen: at 6-month follow-up, weight increased significantly in participants on RPV+DTG, PI+DTG, TDF/FTC+DTG, and TAF/FTC+DTG. After adjusting for age, sex, baseline weight and CD4, naïve status, CDC stage, statin use (use at enrollment and 1-year updated information), and active HCV infection (at enrollment and 1-year updated information), weight increase was confirmed to be significant at 6-month follow-up; further increases at 12-month follow-up were only significant for TDF/FTC+DTG and TAF/FTC+DTG. In the same model, using 3TC/ABC+DTG as the reference, weight change was significantly higher in the TDF/FTC+DTG (*P* = .004) and PI+DTG groups (*P* = .02) at 6-month follow-up. However, in subsequent follow-up, no difference was observed.

![Weight by regimen. Mean weight (kg) at baseline and 6-month, 12-month, 18-month, and 24-month follow-up in people treated with different dolutegravir-containing regimens. Dolutegravir was associated with abacavir/lamivudine in 326 participants, tenofovir disoproxil fumarate/emtricitabine in 148, boosted protease inhibitors in 60, rilpivirine in 45, lamivudine in 75, and tenofovir alafenamide/emtricitabine in 59. Abbreviations: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; FTC, emtricitabine; PI, protease inhibitor; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide.](ofaa195f0001){#F1}

###### 

Weight Change According to DTG-Containing Regimen

  Weight   3TC + DTG   RPV + DTG        PI + DTG   3TC/ABC/DTG    TDF/FTC + DTG   TAF/FTC + DTG                                                 
  -------- ----------- ---------------- ---------- -------------- --------------- --------------- ----- ------------- ----- -------------- ---- --------------
  T1-T0    75          --0.1 ± 0.4      45         0.8 ± 0.3^a^   60              1.2 ± 0.3^a^    326   0.1 ± 0.2     148   1.5 ± 0.3^a^   59   1.3 ± 0.5^a^
  T2-T1    44          1.0 ± 0.4^a^     34         0.6 ± 0.6      51              0.1 ± 0.3       250   0.1 ± 0.2     137   1.0 ± 0.4^a^   14   1.6 ± 0.4^a^
  T3-T2    28          --0.7 ± 0.2^a^   30         0.4 ± 0.3      40              --0.2 ± 0.3     191   --0.3 ± 0.2   115   0.3 ± 0.5      3    --1.0 ± 0.6
  T4-T3    24          --0.3 ± 1.0      27         --0.2 ± 0.4    36              0.3 ± 0.5       150   0.5 ± 0.3     92    0.5 ± 0.3      1    --

T0 = baseline; T1 = 6 months; T2 = 12 months; T3 = 18 months; T4 = 24 months.

Abbreviations: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; FTC, emtricitabine; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

^a^ *P* \< .05 for change from baseline (T1-T0) or previous follow-up visit (T2-T1, T3-T2, T4-T3).

Factors Associated With Weight Gain {#s5}
-----------------------------------

According to our definition, 75 participants (10.5%) became WGs during the whole observation period. In multivariate Cox regression ([Table 3](#T3){ref-type="table"}), higher baseline weight and female sex represented factors that were protective against becoming a WG. Baseline CD4 \<200 cells/mm^3^ and being ART-naïve were associated with higher weight change from baseline. Eradication of HCV infection was suggested as a risk factor, although of borderline significance. With regard to regimens, we used the most used regimen, 3TC/ABC+DTG, as the reference category: HRs were higher for all the remaining regimens, but only significantly so for TDF/FTC+DTG and TAF/FTC+DTG ([Table 3](#T3){ref-type="table"}). The analysis of factors associated with weight gain in patients who were ART-naïve or -experienced is available in the Supplementary Data.

###### 

Cox Regression Analysis for Weight Gain \>10%

                                    Hazard Ratio   95% CI          *P*
  --------------------------------- -------------- -------- ------ -------
  Baseline age (by 5 y)             0.97           0.89     1.06   .48
  Gender F vs M                                                    
  M                                 1.00                           
  F                                 0.54           0.33     0.88   .01
  Baseline weight (by 1 kg)         0.97           0.96     0.99   .002
  Risk factor for HIV acquisition                                  
  Sexual                            1.00                           
  IVDU                              1.23           0.68     2.24   .49
  Other                             0.94           0.56     1.61   .84
  Baseline CD4, cells/mm^3^                                        
  \>500                             1.00                           
  200--500                          0.98           0.64     1.52   .94
  \<200                             1.84           1.15     2.96   .01
  CDC stage                                                        
  A--B                              1.00                           
  C                                 1.40           0.94     2.10   .10
  Status                                                           
  ART-experienced                   1.00                           
  ART-naïve                         2.24           1.20     4.18   .01
  Years of previous ART (by 1 y)    0.99           0.96     1.02   .59
  Statin use                                                       
  Never                             1.00                           
  Since baseline                    1.18           0.55     2.55   .67
  Started after enrollment          1.37           0.49     3.82   .55
  Baseline active HCV                                              
  No                                1.00                           
  Active HCV, untreated             1.23           0.58     2.61   .60
  Active HCV, eradicated            1.84           0.92     3.69   .08
  ART regimen                                                      
  3TC/ABC/DTG                       1.00                           
  3TC + DTG                         1.72           0.82     3.61   .15
  RPV + DTG                         1.37           0.60     3.12   .45
  PI + DTG                          1.33           0.68     2.57   .40
  TDF/FTC + DTG                     1.92           1.23     2.98   .004
  TAF/FTC + DTG                     3.80           1.75     8.23   .0007

The model equation included age, sex, baseline weight, risk factor for HIV acquisition, baseline CD4 and CDC stage, naïve status, ART duration (set at 0 for naïve participants), statin use, HCV eradication during the first year of study, DTG-including regimen. The model for naïve status estimate did not include ART duration.

Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CI, confidence interval; DTG, dolutegravir; FTC, emtricitabine; HCV, hepatitis C virus; IVDU, intravenous drug use; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

Impact of Weight Gain on Lipids and Blood Glucose {#s6}
-------------------------------------------------

To explore the possible effect of weight gain on blood lipids and glucose, we compared TC, HDL, TG, and fasting glucose between 12-month WG and NG participants. One hundred five (14.7%) participants with intermediate weight gain were excluded from this analysis. Thus, we compared 49 WGs vs 526 NGs. The trends of TC, HDL, TG, and fasting glycemia during the study period are shown in [Table 4](#T4){ref-type="table"}. Controlling for age, sex, statin use, and regimen, all these values were not significantly different by weight gain, except for HDL variation, which showed a higher increase in WG participants (*P* = .04).

###### 

Blood Lipids and Glucose Changes in 548 Nongainers and 49 Weight Gainers

                                        NGs              WGs              *P* ^a^
  ------------------------------------- ---------------- ---------------- ----------
  Total cholesterol, mean ± SD, mg/dL                                     BL, .04
  Baseline                              186 ± 46         172 ± 49         .22
  At 6 mo                               186 ± 45         176 ± 52         
  At 12 mo                              184 ± 42         181 ± 46         
  HDL cholesterol, mean ± SD, mg/dL                                       BL, .008
  Baseline                              47 ± 17          40 ± 13          .046
  At 6 mo                               48 ± 16          41 ± 13          
  At 12 mo                              49 ± 15          47 ± 15          
  TC/HDL, median (IQR)                                                    BL, .10
  Baseline                              4.1 (3.2--5.1)   4.3 (3.8--5.3)   .18
  At 6 mo                               3.9 (3.1--4.9)   4.3 (3.3--5.5)   
  At 12 mo                              3.9 (3.1--4.7)   4.0 (3.2--5.0)   
  Triglycerides, median (IQR), mg/dL                                      BL, .75
  Baseline                              117 (87--172)    108 (86--180)    .63
  At 6 mo                               112 (80--162)    119 (88--173)    
  At 12 mo                              107 (79--159)    110 (73--174)    
  Triglycerides/HDL                                                       BL, .16
  Baseline                              2.7 (1.6--4.7)   3.0 (2.0--6.1)   .15
  At 6 mo                               2.5 (1.5--4.1)   2.9 (1.9--5.1)   
  At 12 mo                              2.3 (1.5--4.0)   2.7 (1.4--4.8)   
  Blood glucose, mean ± SD, mg/dL                                         BL, .64
  Baseline                              91 ± 27          90 ± 16          .49
  At 6 mo                               92 ± 23          92 ± 16          
  At 12 mo                              93 ± 22          93 ± 15          

Abbreviations: BL, baseline; HDL, high-density lipoprotein; IQR, interquartile range; NGs, nongainers; TC, total cholesterol; WGs, weight gainers.

^a^Test for repeated measures, adjusted for age, sex, baseline statin use, regimen type.

Obesity and Metabolic Syndrome {#s7}
------------------------------

Out of 608 participants with available baseline BMI, 46 (7.6%) were obese and 186 (30.6%) were overweight. Among overweight participants, 15 (8.1%) crossed the threshold for the obesity definition, and 37 (19.9%) lost enough weight to become normal weight.

At baseline, among 464 (65.1%) participants with complete data for metabolic syndrome evaluation, 26 (5.6%) had metabolic syndrome. Out of 438 without baseline metabolic syndrome, 10 developed it during follow-up, resulting in a rate of 9.9 cases per 1000 person-years (95% CI, 5.0 to 17.7).

DISCUSSION {#s8}
==========

In this work, we described the weight changes in one of the largest cohorts of DTG-treated PWH prospectively followed up in a real-life context. Similar to previous data, we confirmed that PWH gained weight during DTG treatment, especially if naïve to ART \[[@CIT0011], [@CIT0014], [@CIT0017]\]. We also found that people treated with DTG in association with TAF/FTC or TDF/FTC were more prone to experience the weight increase. A possible role of TAF has been previously observed in ART-naïve and -experienced PWH \[[@CIT0013], [@CIT0015], [@CIT0020], [@CIT0024]\] and was confirmed in our work in a real-life context, where TAF was mainly used to treat ART-naïve participants and, despite low numbers, seemed to be linked to nearly 4-fold higher risk of weight gain compared with ABC/3TC + DTG. The reasons underlying this observation remain unclear, despite a possible effect on lipid metabolism having been previously observed for TAF that might in some way also influence fat accumulation \[[@CIT0025], [@CIT0026]\]. It is also possible that the inverse correlation, namely the accumulation of fat during TAF treatment, could be one of the reasons for the elevation of lipid levels that has been observed in the course of TAF treatment. In fact, in the general population, a correlation between visceral fat and higher levels of TG and TC exists, as omental and mesenteric fat play an important role in the hepatic lipid metabolism, contributing to hypertriglyceridemia and low HDL concentrations \[[@CIT0027]\]. However, due to the recent introduction of TAF in clinical practice, observational data are still scarce \[[@CIT0024]\], and more studies will be needed to identify the potential metabolic pathway by which TAF could interfere with fat accumulation or blood lipid metabolism. Moreover, we did not observe different effects on lipids between WGs and NGs, or participants treated with TDF, a drug considered to have a neutral effect on lipids \[[@CIT0028]\], who experienced nearly double the risk of weight gain compared with those on ABC/3TC in SCOLTA. The effect of TDF/FTC on weight has been studied in the past, but the results were not univocal. No effect was found in previous studies in naïve \[[@CIT0015], [@CIT0019]\] or experienced PWH \[[@CIT0018]\], but in a recently published pooled analysis of 8 randomized controlled clinical trials of treatment-naïve PWH initiating ART between 2003 and 2015, Sax et al. showed that PWH treated with TDF gained more weight compared with those treated with AZT (2.07 kg; 95% CI, 1.84 to 2.30; vs 0.39 kg; 95% CI, --0.57 to 1.34) \[[@CIT0015]\]. Then, according to our results, tenofovir could influence weight gain in both its prodrug forms, TDF and TAF, but on the contrary, previous studies have found that PWH on ABC/3TC gained more weight than those on tenofovir \[[@CIT0009], [@CIT0029]\], whereas in other studies both ABC/3TC and TDF/FTC had a neutral effect on weight, BMI, and lean body mass changes \[[@CIT0015], [@CIT0019]\]. The discordant results of the abovementioned studies might reside in different patient populations and unmeasured confounding factors; dietary, psychological, social, and economic factors can play a role. Moreover, it is possible that not only the single drugs, but also their association could increase the risk of gaining weight, although with an unknown mechanism, or simply enhancing the effect of DTG in certain combinations.

Last, but not least, HIV infection itself and the virus activity may also play a role in weight changes. In our study, ART-naïve PWH and those with the lowest CD4 T-cell counts were at higher risk of gaining weight, supporting the hypothesis that weight gain might be explained, at least in part, as a "return to health" phenomenon, the result of successfully suppressing viral replication, controlling inflammation, and normalizing resting energy expenditure \[[@CIT0030]\]. Of note, in healthy HIV-uninfected males, weight did not change with use of either TDF/FTC or cabotegravir \[[@CIT0031], [@CIT0032]\].

We also found higher risk of being a WG for male PWH. This is in contrast with literature data collected in PWH \[[@CIT0009], [@CIT0013], [@CIT0015]\], where black females especially were at higher risk. However, in our study, participants were mainly Caucasian, and women were little represented. The difference in country of origin and ethnicity might indeed play a role in the evaluation of weight gain and gender differences, as in developed countries more men than women are overweight and obese, whereas in developing countries overweight and obesity are more prevalent in women \[[@CIT0033]\]. Moreover, in the general population living in developed countries, overweight and obesity are expected to peak in men at about 55 years of age, different from women, in whom the peak is expected at a slightly older age, closer to 60 years \[[@CIT0033]\]. PWH enrolled in the present study, mainly male and about 50 years old, might be more representative of the general population of developed countries than PWH enrolled in previous studies; our findings may be similar to the recently presented data from the Swiss cohort, where male PWH were shown to be at greater risk of weight gain than women \[[@CIT0034]\].

Finally, we found that the incidence of MS was about 10 cases per 1000 person-years. A higher prevalence of metabolic syndrome in PWH than in the general population has been reported in the past \[[@CIT0035]\], with an estimated incidence in developed countries ranging between 8 and 14 cases per 100 person-years \[[@CIT0036]\]. Although the follow-up was limited in our study, we did not find an excess incidence of metabolic syndrome. Moreover, blood levels of TC, TC/TG, and fasting glucose did not change differently in WGs and NGs in our study, suggesting that the metabolic impact of weight gain was low in our cohort.

This study has several potential limitations. First, owing to the observational nature of the study, PWH were not randomly assigned to drug therapies, and confounding bias could have occurred, based on clinicians' decisions to prescribe different drug associations in PWH with different baseline characteristics. In addition, dietary habits and personal choices or sociopsychological conditions influencing weight loss or gain were not recorded. Finally, our ability to detect incident obesity and metabolic syndrome might be limited by the lack of complete data to define these events in part of the study population and by the relatively short follow-up.

In conclusion, in our study, naïve PWH and those with lower CD4 counts were at higher risk of weight gain, and TAF/FTC and TDF/FTC were the drugs that in combination with DTG had the highest impact on weight. The real clinical implications of weight gain on cardiovascular risk still need to be defined, whereas weight gain in people who are not overweight should be considered a favorable effect, as it has a demonstrated benefit in terms of mortality \[[@CIT0039]\]. Moreover, weight gain seemed to have no impact on fasting glucose or cholesterol levels in our cohort, where, despite weight gain, we did not find a high impact on incident obesity and MS. The fact that studies with differing designs and populations have found different risk factors for weight gain in the literature highlights how treatment should always be tailored to the individual patient, without falling to the temptation of generalizing the study results to all PWH.
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